Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study

CONCLUSION: Treatment with erenumab 70 mg once monthly demonstrated favorable efficacy and safety findings in Japanese patients with EM or CM.PMID:34153117 | DOI:10.1111/head.14138

Source: Headache - June 21, 2021 Category: Neurology Authors: Takao Takeshima Fumihiko Sakai Koichi Hirata Noboru Imai Yasuhiko Matsumori Ryuji Yoshida Cheng Peng Sunfa Cheng Daniel D Mikol Source Type: research